Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 3, 2026

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

16.0K

Cytogenetic prognostication within medulloblastoma subgroups.

David J H Shih1, Paul A Northcott, Marc Remke

  • 1David J.H. Shih, Marc Remke, Vijay Ramaswamy, Betty Luu, Yuan Yao, Xin Wang, Adrian M. Dubuc, Livia Garzia, John Peacock, Stephen C. Mack, Xiaochong Wu, Adi Rolider, A. Sorana Morrissy, Florence M.G. Cavalli, Claudia C. Faria, Stephen W. Scherer, Uri Tabori, Cynthia E. Hawkins, David Malkin, Eric Bouffet, James T. Rutka, and Michael D. Taylor, Hospital for Sick Children; David J.H. Shih, Marc Remke, Vijay Ramaswamy, Yuan Yao, Xin Wang, Adrian M. Dubuc, John Peacock, Stephen C. Mack, and Michael D. Taylor, University of Toronto, Toronto; Boleslaw Lach, McMaster University, Hamilton, Ontario; Jennifer A. Chan, University of Calgary, Calgary, Alberta; Steffen Albrecht, Adam Fontebasso, and Nada Jabado, McGill University, Montreal, Quebec, Canada; Paul A. Northcott, Andrey Korshunov, Marcel Kool, David T.W. Jones, and Stefan M. Pfister, German Cancer Research Center; Stefan M. Pfister, University Hospital Heidelberg, Heidelberg; Ulrich Schüller, Ludwig-Maximilians-University, Munich; Stefan Rutkowski, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Karel Zitterbart, Masaryk University School of Medicine; Karel Zitterbart and Leos Kren, University Hospital Brno, Brno, Czech Republic; Toshihiro Kumabe and Teiji Tominaga, Tohoku University Graduate School of Medicine, Sendai, Japan; Young Shin Ra, University of Ulsan, Asan Medical Center; Ji-Yeoun Lee, Byung-Kyu Cho, Seung-Ki Kim, and Kyu-Chang Wang, Seoul National University Children's Hospital, Seoul; Shin Jung, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Chonnam, South Korea; Peter Hauser and Miklós Garami, Semmelweis University, Budapest; László Bognár and Almos Klekner, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary; Shenandoah Robinson, Boston Children's Hospital; Scott L. Pomeroy, Harvard Medical School, Boston, MA; Ali G. Saad, University of Arkansas for Medical Sciences, Little

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|February 5, 2014
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

NMDA receptor mediated tonic excitatory currents are elicited by EAAT inhibition on human neocortical pyramidal neurons.

Frontiers in synaptic neuroscience·2026
Same author

Deep learning-driven 3-D histopathology method: a pipeline for cellular-resolution myocarditis analysis.

American journal of physiology. Heart and circulatory physiology·2026
Same author

LDLR-OPN Interaction Drives COVID-19 Myocarditis Through Monocyte Recruitment.

JACC. Basic to translational science·2026
Same author

Poorly Differentiated Signet-Ring Cell Gastroesophageal Carcinoma in a Child With No Detectable Genetic Predisposition: Report of a Rare and Highly Aggressive Tumor.

Pediatric blood & cancer·2026
Same author

The role of miRNAs in the development of brain metastases originating from lung adenocarcinoma.

Frontiers in genetics·2026
Summary

Identifying specific molecular biomarkers for medulloblastoma subgroups significantly improves patient prognostication. This panel aids in tailoring treatments for very high-risk and very low-risk patients.

Area of Science:

  • Pediatric oncology
  • Molecular diagnostics
  • Cancer genomics

Background:

  • Medulloblastoma has four molecular subgroups: WNT, SHH, Group 3, and Group 4.
  • Current treatment stratification relies on clinical factors like age and stage.
  • Subgroup-specific genetic differences necessitate improved prognostication tools.

Purpose of the Study:

  • To identify molecular biomarkers for improved medulloblastoma prognostication.
  • To develop risk stratification models combining clinical and molecular data.
  • To validate the utility of cytogenetic biomarkers in identifying high-risk patients.

Main Methods:

  • Identified biomarkers from 673 medulloblastomas globally.
  • Developed risk models using multivariable Cox proportional hazards analysis.

More Related Videos

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

11.6K
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

2.1K

Related Experiment Videos

Last Updated: May 3, 2026

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

16.0K
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

11.6K
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

2.1K
  • Validated six FISH biomarkers (GLI2, MYC, chr11, chr14, 17p, 17q) on 453 tissues.

    • Main Results:

    • Subgroup information enhances survival model accuracy over clinical biomarkers alone.
    • Most cytogenetic biomarkers are subgroup-specific in their prognostic value.
    • Six FISH biomarkers reliably identified very low-risk and very high-risk patients in SHH, Group 3, and Group 4.

    Conclusions:

    • Combining subgroup and cytogenetic biomarkers with clinical factors improves prognostication.
    • A small panel of cytogenetic biomarkers effectively stratifies risk.
    • These biomarkers can guide therapy intensification or de-escalation in clinical trials.